Sector: Health Care
Director information for CASTLE BIOSCIENCES INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Daniel M. Bradbury | Board Chair; Chairman of the Board; Class II Director (Chair) | 64 | ["Currently serves on the board of directors of Equillium, Inc. and Vivani Medical Inc.","Previously served as an executive and CEO of Equillium Inc.","Managing member of BioBrit, LLC.","Previously served as President, CEO and Director of Amylin Pharmaceuticals, Inc.","Serves on the board of directors of numerous privately held companies.","Holds a B.S. degree in pharmacy from Nottingham University","Diploma in Management Studies from University of West London of Higher Education in the United Kingdom.","extensive experience as a life sciences executive","other executive experience","boards of directors experience"] | [] | 2026 |
| Daniel M. Bradbury, Chair | Chair | ["Commercial Execution Experience","Life Science Industry Experience","Financial Analysis & Control Experience","Digital Health","Health System (HE) Experience","R&D Scientific Leadership","Regulatory/Lab Services Reimbursement"] | [] | 2026 | |
| Derek J. Maetzold | President and CEO; President and Chief Executive Officer; Class III Director (CEO) | 64 | ["Commercial Execution Experience","Life Science Industry Experience","Financial Analysis & Control Experience","Digital Health","Health System Experience","R&D Scientific Leadership","Regulatory/Lab Services Reimbursement","Diversity of Skills, Background, and Perspective","Cybersecurity","Founded Castle Biosciences","Leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation, Integrated Communications, Amylin Pharmaceuticals, and Sandoz Pharmaceuticals","Currently serves as a director of PreludeDx, Coalition for 21st Century Medicine and IMPACT Melanoma","Contributed to the discovery, development and commercialization of multiple diagnostic tests in cancers","Co-authored multiple scientific publications","Co-inventor of technologies at Castle Biosciences and Encysive Pharmaceuticals","B.S. degree in Biology from George Mason University","Completed additional coursework at the University of Calgary Health Sciences Center","Completed MBA program at the University of California, Riverside","Health System (HE) Experience"] | [] | 2026 |
| Ellen Goldberg | Founder and President; Class I Director | 52 | ["Founder and President of CHORD Consulting","Previously served as Vice President of Marketing at Crescendo Biosciences","Led marketing at Genomic Health","Holds a B.S. degree in chemistry from Yale University","Holds a M.S. in chemistry and an MBA from Stanford University","Commercial Execution Experience","Life Science Industry Experience","Digital Health","Regulatory/ Lab Services Reimbursement","Diversity of Skills, Background, and Perspective","Founder and President of CHORD Consulting since 2011","Vice President of Marketing at Crescendo Bioscience","Strategy consultant with Booz Allen & Hamilton","Developed new products at ALZA Corporation","M.S in Chemistry and MBA from Stanford University","B.S. in Chemistry from Yale University","Fellow of the Aspen Institute’s Health Innovators Fellowship Program","Financial Analysis & Control Experience","Regulatory/Lab Services Reimbursement"] | ["Comp. Committee (Chair)","Nominating and Corporate Governance Committee","Compensation Committee (Chair)"] | 2026 |
| G. Bradley Cole | Chairman of the Castle Audit Committee; Class III Director | 70 | ["Commercial Execution Experience","Life Science Industry Experience","Financial Analysis & Control Experience","Digital Health","Regulatory/Lab Services Reimbursement","Cybersecurity","Chief Financial Officer of Genomic Health, Inc.","General Manager, Precision Oncology at Exact Sciences Corporation","Extensive experience in finance and operations as a public company executive","Knowledge of the diagnostics industry","Vice Chairman of the Board of Trustees of Biola University","Health System (HE) Experience"] | ["Audit Committee (Chair)","Comp. Committee","Audit Committee","Compensation Committee"] | 2026 |
| Kimberlee S. Caple | Independent Director; Class III Director | 64 | ["Life Science Industry Experience","Financial Analysis & Control Experience","Health System Experience","R&D Scientific Leadership","Regulatory/Lab Services Reimbursement","Diversity of Skills, Background, and Perspective","Extensive experience in life science","Strategic leadership skills","Former President of Genetic Science Division at Thermo Fisher Scientific","Digital Health"] | ["Audit Committee","Nominating and Corporate Governance Committee"] | 2026 |
| Miles D. Harrison | CEO and President; Class I Director | 61 | ["Previously served as the North American President and General Manager at Galderma Laboratories, L.P.","Also served as Galderma’s Vice President and General Manager of the Consumer Business Unit","Holds a B.S. degree in geography from Sheffield Hallam University in the United Kingdom","Commercial Execution Experience","Life Science Industry Experience","Financial Analysis & Control Experience","Experience in dermatology","Strategic leadership skills","Executive in the pharmaceutical and consumer healthcare industry","Co-founder of medical aesthetics company 'Novaestiq'","Former North American President and General Manager of Galderma Laboratories, L.P.","Leadership positions at Novartis International AG","Digital Health","Health System (HE) Experience","Regulatory/Lab Services Reimbursement"] | ["Comp. Committee","Nominating and Corporate Governance Committee","Compensation Committee"] | 2026 |
| Rodney Cotton | CEO of Cotton Ventures, LLC; Class II Director | 66 | ["Previously served as Senior Vice President, Chief of Staff and Head of Strategy and Transformation at Roche Diagnostics.","Also served as Interim Head of Communications and Senior Vice President, Commercial Operations/West Zone.","Serves on the board of directors of numerous privately held companies.","Holds a B.A. in Biological Sciences & Technology from the University of California, Santa Barbara.","M.S. in Strategic Management from the University of Southern California.","MBA from the California State University Dominguez Hills.","Senior Vice President, Chief of Staff and Head of Strategy and Transformation at Roche Diagnostics","Interim Head of Communications at Roche Diagnostics","Senior Vice President, Commercial Operations at Roche Diagnostics","CEO of Cotton Ventures, LLC","Board member of various privately held pharmaceutical, life sciences, venture capital and technology companies","Mergers & Acquisition Executive Program at Harvard Business School","Director’s Consortium Executive Program at Stanford Graduate School of Business","MBA from California State University Dominguez Hills","M.S. in Strategic Management from University of Southern California","B.A. in Biological Sciences & Technology from University of California, Santa Barbara","Life Science Industry Experience","Health System (HE) Experience","Digital Health","Regulatory/Lab Services Reimbursement"] | ["Audit Committee","Comp. Committee","Compensation Committee"] | 2026 |
| Tiffany P. Olson | Class I Director; Chair | 66 | ["Previously served as President of Nuclear & Precision Health Solutions at Cardinal Health","Previously served as President at NaviMed","CEO and President of Roche Diagnostics Corporation","Holds a B.S. degree in business from University of Minnesota","Holds an MBA from the University of St. Thomas","Commercial Execution Experience","Life Science Industry Experience","Financial Analysis & Control Experience","Digital Health","Health System Experience","Diversity of Skills, Background, and Perspective","Extensive experience in life science","Strategic leadership skills as an executive in the pharmaceutical, diagnostics and health services industry","Health System (HE) Experience","Regulatory/Lab Services Reimbursement"] | ["Audit Committee","Nominating and Corporate Governance Committee (Chair)","Nominating and Corporate Governance Committee"] | 2026 |
